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Abstract: Rho GTPases are overexpressed and hyperactivated in many cancers, including 
breast cancer. Rho proteins, as well as their regulators and effectors, have been implicated 
in mitosis, and their altered expression promotes mitotic defects and aneuploidy. 
Previously, we demonstrated that p190B Rho GTPase activating protein (RhoGAP) 
deficiency inhibits ErbB2-induced mammary tumor formation in mice. Here we describe  
a novel role for p190B as a regulator of mitosis. We found that p190B localized to 
centrosomes during interphase and mitosis, and that it is differentially phosphorylated during 
mitosis. Knockdown of p190B expression in MCF-7 and Hela cells increased the incidence 
of aberrant microtubule-kinetochore attachments at metaphase, lagging chromosomes at 
anaphase, and micronucleation, all of which are indicative of aneuploidy. Cell cycle analysis 
of p190B deficient MCF-7 cells revealed a significant increase in apoptotic cells with a 
concomitant decrease in cells in G1 and S phase, suggesting that p190B deficient cells die 
at the G1 to S transition. Chemical inhibition of the Rac GTPase during mitosis reduced the 
incidence of lagging chromosomes in p190B knockdown cells to levels detected in control 
cells, suggesting that aberrant Rac activity in the absence of p190B promotes chromosome 
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segregation defects. Taken together, these data suggest that p190B regulates chromosome 
segregation and apoptosis in cancer cells. We propose that disruption of mitosis may be 
one mechanism by which p190B deficiency inhibits tumorigenesis.  
Keywords: p190B RhoGAP; mitosis; chromosome segregation; centrosome; aneuploidy; 
Rho GTPases; breast cancer 
 
1. Introduction 
The Rho signaling network that includes Rho GTPases and their regulators and effectors regulates  
a diverse set of cellular functions such as cell cycle progression, mitosis, migration, apoptosis, 
morphogenesis, and cytoskeletal organization [1]. Rho GTPases are overexpressed and hyperactivated 
in several types of cancer, including breast cancer [2,3], and aberrant Rho signaling has been 
implicated in all stages of cancer development and progression (for review see [4]). 
Aneuploidy and genomic instability are features of most solid tumors [5], and disruption of mitosis 
and cytokinesis facilitates these processes. A number of studies have implicated Rho GTPases and their 
regulators and effectors in centrosome duplication, mitotic spindle formation, kinetochore-microtubule 
attachments, and cytokinesis [6–10]. Perturbation of any of these processes can lead to abnormal 
chromosome segregation and aneuploidy. 
Rho GTPases cycle between active GTP-bound and inactive GDP-bound states, and tight regulation 
of Rho GTPase activity is important for proper control of a diverse set of cellular functions [11]. The 
Rho GTPase cycle is positively regulated by guanine nucleotide exchange factors (GEFs) and 
negatively regulated by the Rho GTPase activating proteins (RhoGAPs) and guanine nucleotide 
dissociation inhibitors (GDIs). Altered expression of Rho regulators has been shown to affect 
mammary tumor formation in mice [12–14]. Previous studies from our laboratory demonstrated that 
heterozygous expression of p190B, a major regulator of Rac and RhoA [15,16], potently inhibited 
tumor formation and metastases in the MMTV-Neu mouse mammary tumor model [17]. Conversely, 
ectopic expression of p190B in the mammary epithelium of MMTV-Neu mice increased both tumor 
burden and metastasis [18]. The objective of the current study was to identify potential mechanisms by 
which p190B influences tumorigenesis. Because aberrant Rho signaling has been implicated in several 
stages of mitosis and cytokinesis and the closely related p190A RhoGAP has been shown to be an 
important regulator of cytokinesis [19–22], we hypothesized that altered p190B expression may also 
disrupt mitotic processes. Here we show that p190B affects chromosome segregation in MCF-7 breast 
cancer cells and Hela cervical cancer cells. 
2. Results 
2.1. P190B RhoGAP Localizes to Centrosomes and Is Phosphorylated During Mitosis 
To begin to elucidate the function of p190B, we first investigated its cellular localization by 
immunofluorescence staining. In MCF-7 breast cancer cells, we detected GFP-tagged p190B and 
endogenous p190B at the centrosomes during interphase, as well as endogenous p190B at  
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the centrosomes during mitosis (Figure 1A). To determine whether p190B expression levels are 
regulated during mitosis, we measured protein levels throughout mitosis by Western blot in 
nocodazole-synchronized MCF-7 cells. No significant changes in p190B protein levels were detectable 
in mitotic cells from three independent experiments (data not shown). However, a slower-migrating 
p190B band was apparent in mitotic cell lysates that is consistent with protein phosphorylation  
(Figure 1B), and p190B is phosphorylated at both Ser/Thr and Tyr residues [23,24]. A proteomic study 
of mitotic phosphoproteins showed that p190B is selectively phosphorylated during mitosis on one Thr 
and nine Ser residues [25]. The Ser/Thr residues are present at the C-terminal portion of the middle 
domain and flank Tyr1105 (Figure 1D), which corresponds to a Src kinase consensus site found in 
p190A [26,27]. To determine whether p190B is also selectively tyrosine phosphorylated during 
mitosis, we performed immunoprecipitation of phospho-Tyr proteins in lysates prepared from 
asynchronous and nocodazole-treated mitotic cell populations and probed for p190B on a Western 
blot. A single band of approximately 190 kDa was observed in the asynchronous and mitotic lysates, 
whereas an additional slower migrating band was observed in the mitotic cell lysate (Figure 1C). These 
data suggest that p190B is phosphorylated on tyrosine residues throughout the cell cycle and that it is 
differentially phosphorylated during mitosis. These results together with published studies [25] 
indicate that p190B localizes to centrosomes and that it is differentially phosphorylated during mitosis. 
2.2. P190B Deficiency Enhances Chromosome Segregation Defects in MCF-7 and Hela Cells 
To better understand the functional role of p190B in mitosis, we used RNA interference to 
knockdown p190B protein expression in both MCF-7 and Hela cells. MCF-7 cells transfected with 
siRNA directed against p190B (labeled KD1 and KD2) exhibited an approximately 75% reduction  
in p190B protein levels compared to cells transfected with a control (CTL) non-targeting siRNA 
(Figure 2A). Hela cells transfected with KD1 exhibited similar levels of protein knockdown (data not 
shown). Neither of the siRNAs targeting p190B affected the expression levels of the closely related 
p190A protein as determined by Western blot (Figure 2A). To determine how knockdown of p190B 
affects cell cycle progression, we examined the cell cycle profile of MCF-7 cells transfected with  
non-targeting and p190B-targeting siRNA (Figure 2B). Cells were fixed and stained with propidium 
iodide 48 h after transfection and analyzed by flow cytometry. We observed a significant increase in the 
apoptotic, sub-G1, population in knockdown cells compared to controls (21.2% vs. 9.3%, p < 0.001), and 
a concomitant decrease in the G1 and S populations (44.0% vs. 54.7% combined G1/S population,  
p < 0.001). These data suggest that loss of p190B leads to cell death at the G1/S transition. 
Next we wanted to determine whether loss of p190B caused mitotic defects in the cells  
that successfully entered mitosis. For this, we quantified lagging chromosomes at anaphase in 
nocodazole-synchronized MCF-7 and Hela cells transfected with control non-targeting or  
p190B-targeting siRNA. Lagging chromosomes are indicative of mitotic spindle abnormalities and are 
a known cause of aneuploidy [28]. Interestingly, p190B deficiency resulted in a significant increase in 
the number of cells exhibiting lagging chromosomes at anaphase (52.3% and 52.5% in KD1 and KD2 
vs. 35.4% in control, p = 0.012 and 0.030, respectively, for MCF-7; 33.8% in KD1 vs. 24.8% in 
control, p = 0.012 for Hela) (Figure 2C). In order to determine whether the observed lagging 
chromosomes resulted in aneuploidy in our cells, we quantified micronuclei, which are indicative of 
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extra genetic material that can result from improper chromosome segregation [29]. P190B deficiency 
also resulted in a significant increase in the percentage of MCF-7 and Hela cells containing 
micronuclei at interphase (10.5% and 10.4% in KD1 and KD2 vs. 6.99% in control, p = 0.027 and 
0.040, respectively, for MCF-7; 9.4% in KD1 vs. 6.9% in control, p = 0.019 for Hela) (Figure 2D). 
Because the related p190A RhoGAP plays an important role in cytokinesis [19–22], we also asked 
whether p190B deficiency in MCF-7 cells affected the incidence of multinucleated cells, which are 
indicative of failed cytokinesis. We stained cells with an antibody against E-cadherin to clearly 
delineate individual cells and quantified the percentage of cells with multiple nuclei. As shown in 
Figure 2E, p190B deficiency did not affect the rate of multinucleation in MCF-7 cells (2.5% and 2.9% 
in KD1 and KD2 vs. 2.5% in control, p = 0.98 and p = 0.53, respectively). Together these data indicate 
that p190B loss in cancer cells increases abnormal chromosome segregation during anaphase, but that 
its function is dispensable for cytokinesis. 
2.3. P190B Deficiency Increases the Incidence of Abnormal Microtubule-Kinetochore Attachments 
The major cause of lagging chromosomes at anaphase is the phenomenon of merotelic attachment, 
where microtubules emanating from both spindle poles attach to the same kinetochore [30]. This 
frequently results in missegregation as the chromosome remains suspended between the two poles until 
one microtubule exerts a stronger pull. We therefore quantified merotelic attachments in metaphase 
MCF-7 cells transfected with control or p190B-targeting siRNA using high-resolution confocal 
microscopy. We observed that p190B deficiency resulted in a significant increase in the number of 
cells containing merotelic attachments compared to control cells (60.0% and 66.7% in KD1 and KD1 
vs. 22.5% in control, p = 0.008 and 0.003, respectively) (Figure 3), suggesting that loss of p190B 
perturbs microtubule-kinetochore attachments. The persistence of this defect into anaphase may reflect 
a greater frequency of microtubule-kinetochore misattachment in the p190B deficient cells or failure of 
the cells to correct the misattachments. 
2.4. Localization of the Chromosomal Passenger Complex Proteins Survivin and Aurora B Is Not 
Altered in p190B Deficient Cells 
In order to untangle the mechanisms by which p190B deficiency leads to defects in chromosome 
segregation, we examined the levels of Survivin and Aurora B, two members of the chromosomal 
passenger complex (CPC), which is known to play an important role in correcting merotelic 
attachments [31]. We quantified the fluorescence intensity in metaphase MCF-7 cells stained for 
Survivin and Aurora B. Fluorescence intensity for each cell was normalized to the intensity of the 
kinetochore marker CREST. We found a modest decrease in the intensity of Survivin (2.5 in KD1 vs. 
3.3 in control, p = 0.018), and no significant difference in the intensity Aurora B (3.9 in KD1 vs. 3.0 in 
control, p = 0.72) (Figure 4), suggesting that the CPC is not differentially activated in the p190B 
deficient cells compared with controls. 
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Figure 4. Localization of the CPC proteins Survivin and Aurora B at kinetochores in 
metaphase MCF-7 cells is not affected by p190B deficiency. Representative confocal images 
of metaphase control and p190B deficient MCF-7 cells immunostained with antibodies to 
detect Survivin, Aurora B, or CREST anti-serum are shown. Fluorescence intensities of 
Survivin and Aurora B normalized to CREST are graphed. Data is representative of at least 
30 cells per group quantified from 3 independent experiments. 
 
2.5. Inhibition of Rac Reduces Chromosome Segregation Defects in p190B Deficient Cells 
Rho GTPases, including Cdc42, RhoA, and Rac1, are important regulators of microtubule 
polymerization and stability in migrating cells [32]. However, the contribution of Rho GTPases to 
microtubule function during mitosis is not well understood. P190B is a known inhibitor of Rac and 
RhoA [15,16], and our previous studies have implicated p190B as an important regulator of Rac 
activity during mammary tumorigenesis [17]. We therefore hypothesized that elevated Rac activity 
may perturb microtubule dynamics to increase the incidence of lagging chromosomes in the p190B 
deficient cells. To test this, MCF-7 cells transfected with control or p190B-targeting siRNA were 
arrested with nocodazole and treated with the Rac inhibitor NSC 23766 at the time of release from 
nocodazole. We then quantified the percentage of anaphase cells with lagging chromosomes and found 
that treatment with the Rac inhibitor restored the percentage of lagging chromosomes to control  
levels (58.7% lagging chromosomes in KD1 with Rac inhibitor vs. 75.0% in KD1 without inhibitor,  
p = 0.0004) (Figure 5A). This experiment was repeated in Hela cells with similar results (38.0% 
lagging chromosomes in KD1 with Rac inhibitor vs. 25.7% in KD1 without inhibitor, p = 0.02)  
(Figure 5B). These data suggest that elevated Rac activity in p190B deficient cells is responsible, at 
least in part, for the increase in chromosome segregation defects detected in p190B knockdown cells. 
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affected by p190B loss. Microtubule attachments to kinetochores during mitosis are highly 
dynamic [37], and Rho GTPases are important regulators of microtubules dynamics [32]. We therefore 
considered the possibility that deregulation of Rac, a direct target of p190B [16], might perturb 
microtubule-kinetochore attachments and chromosome segregation in p190B deficient cells. Treatment 
of mitotic cells with the Rac inhibitor NSC 23766 reduced the incidence of lagging chromosomes to 
control levels, suggesting that altered Rac activity in the p190B deficient cells enhances chromosome 
segregation defects in MCF-7 and Hela cells. 
Recent studies investigating aneuploidy as a potential cause of cancer have revealed that large-scale 
aneuploidy causes mitotic catastrophe and has a tumor suppressor function, while small-scale aneuploidy 
allows daughter cells to evade cell death and may promote tumorigenesis [38]. While we cannot directly 
compare the effects of altered p190B expression in MCF-7 and Hela cells to the stochastic process of 
tumor formation in vivo, we hypothesize that p190B may affect mammary tumorigenesis by disrupting 
mitosis and promoting varying degrees of aneuploidy. Future studies will be required to determine the 
contribution of p190B’s mitotic functions to tumor formation and progression. 
4. Experimental Section 
4.1. Cell Culture 
MCF-7 human breast cancer cells stably expressing the rtTA transgene [39] and Hela cells  
(ATCC) were used for all in vitro experiments. MCF-7 cells were cultured in growth medium (DMEM  
high-glucose, 10% Tet-System FBS, 1% insulin, 1% sodium pyruvate, with or without geneticin 
antibiotic) in 5% CO2 at 37 °C. Hela cells were cultured in growth medium (DMEM high-glucose, 
10% FBS, with or without gentamicin). Assays were performed in 8-well chamber slides, glass 
coverslips, or culture dishes (BD Biosciences, Franklin Lakes, NJ, USA). 
4.2. Transfection and Synchronization 
For knockdown experiments, cells were seeded at 10,000 cells per well in an eight-well chamber 
slide or 500,000 cells per 60 mm plate in antibiotic-free growth medium at day 1 and allowed to grow 
for 18–24 h at 5% CO2 at 37 °C. Cells were transfected on day 2 with Oligofectamine transfection 
reagent (Invitrogen, Camarillo, CA, USA) and 100 nM final concentration of siRNA against p190B, or 
a scrambled control siRNA. Two siRNAs (Dharmacon, Chicago, IL, USA) against p190B were used 
(#1: GCUGAUACAACCACAAUUA and #2: GGAAUCAGUUAAACACAAU. For some 
experiments, cells were arrested at prometaphase by treatment with 40 ng/mL nocodazole (Sigma, St. 
Louis, MO) 24–30 h after siRNA transfection. Arrested cells were then released by addition of fresh 
growth medium the following day (48 h after transfection) and incubated for 30–90 min to enrich for 
cells in metaphase and anaphase. The zero time point cells were not washed with fresh medium prior 
to fixation. Asynchronous cells were not treated with nocodazole. 
Transfection of GFP tagged p190B plasmid (Origene, Rockville, MD, USA) into MCF-7 cells for 
immunostaining and localization was done using 0.5–1 μg of plasmid and 1.5 μL Fugene 6 transfection 
reagent (Roche) per well of 12-well culture plate. Cells were plated at 100,000 per well, grown 
overnight, and then transfected with plasmid. Cells were fixed and stained 48 h after transfection. 
Cancers 2012, 4 485 
 
 
4.3. Antibodies 
The following antibodies were used for immunofluorescence staining: α-tubulin (1:500, Abcam, 
Cambridge, MA, USA), HEC1 (1:500, clone 9G3.23, Novus Biologicals, Littleton, CO, USA), 
pericentrin (1:200, Abcam), Survivin (1:50, Santa Cruz; Biotechnology, Inc., Santa Cruz, CA, USA), 
Aurora B (1:1000, BD Transduction Laboratories, San Jose, CA, USA), and CREST serum (1:1000, 
Immunovision, Springdale, AR, USA). The following antibodies were used to probe Western blots: 
p190B (1:250, BD Transduction Laboratories), p190A (1:1000, BD Transduction Laboratories), β-
actin (1:2000, Sigma, St Lois, MO, USA). For immunoprecipitation of tyrosine-phosphorylated 
proteins, p-Tyr antibody (BD Transduction Laboratories) was used. 
4.4. Immunoprecipitation 
Asynchronous and nocodazole synchronized MCF-7 cells were lysed with RIPA buffer (150 mM 
NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, and 10 mM Tris, pH 7.5), and 300 μg 
of protein were incubated with 4 μg p-Tyr antibodies rocking overnight at 4 °C. The lysate and 
antibodies were subsequently incubated with protein A/G beads (Thermo Scientific, Rockford, IL, 
USA) rocking at room temperature for 2 h. Beads were washed several times in RIPA buffer to remove 
unbound proteins. Beads were boiled in denaturing SDS-PAGE loading dye buffer for 10 min and 
centrifuged. The supernatant was used for subsequent SDS-PAGE and Western blotting. 
4.5. Preparation of Cell Lysates and Western Blotting 
Cells were lysed using RIPA buffer with protease inhibitor cocktail (Roche or Thermo Scientific) 
and phosphatase inhibitors (sodium fluoride and sodium orthovanadate) on ice for 10 min, and lysates 
were cleared by centrifugation and immediately frozen in aliquots. Protein concentrations were 
determined using the BCA Assay (Thermo Scientific). Proteins were separated by SDS-PAGE and 
transferred to PVDF membrane (Millipore, Bedford, MA, USA). Membranes were blocked in 5% milk 
in Tris-buffered saline with 0.05% Tween 20 (TBST) followed by incubation with antibodies 
overnight at 4 °C in blocking buffer or 3% BSA/TBST solution. Secondary HRP-conjugated antibody 
was applied for 45–60 min in milk/TBST. Blots were incubated with chemiluminescence reagents 
(Thermo Scientific or GE) and imaged using a Kodak Gel Logic 1500 system or by exposure to 
radiological film. Relative protein expression was quantified by densitometry using ImageJ software, 
and protein expression was normalized to β-actin levels. 
4.6. Immunofluorescence Staining 
Cells were extracted for 10 min at 37 °C in extraction buffer (100 mM PIPES, 1 mM MgCl2, 1 mM 
CaCl2, 0.5% Triton X-100, pH 6.8), fixed for 20 min at 37 °C in freshly prepared 2–4% 
paraformaldehyde in PBS, permeabilized for 10 min at room temperature in 0.5% Triton X-100 in 
PBS, washed 3 times for 5 min each in glycine wash buffer (130 mM NaCl, 7 mM Na2HPO4, 3.5 mM 
NaH2PO4, and 100 mM glycine), blocked for 30 min in IF buffer (130 mM NaCl, 7 mM Na2HPO4,  
3.5 mM NaH2PO4, 7.7 mM NaN3, 0.1% BSA, 0.2% Triton X-100, and 0.05% Tween-20) plus 10% 
goat serum, incubated with primary antibodies in blocking buffer for 1 h at room temperature, washed  
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three times for 5 min each in IF buffer, incubated with secondary antibodies conjugated with Alexa 
555 and Alexa 488 diluted 1:1000 in blocking buffer for 1 h, washed 3 times in IF buffer, incubated 
with To-Pro-3 (Invitrogen) diluted 1:200 in PBS for 15 min, washed with PBS, and mounted with 
Vectashield mounting medium with DAPI (Vector Laboratories, Burlingame, CA, USA). Images were 
captured using a Zeiss LSM710 scanning confocal microscope with Zen imaging software. For 
fluorescence intensity quantification of Survivin, Aurora B, and CREST, images of metaphase cells 
were captured using equivalent zoom and gain settings and then analyzed for intensity using Zen 
software. Intensity values for Survivin and Aurora B were normalized to the CREST intensity value of 
the same cell. 
4.7. Inhibitor Experiments 
Rac inhibitor experiments were performed using the siRNA transfection protocol outlined above. 
Rac inhibitor, NSC 23766 (Tocris Bioscience, Minneapolis, MN, USA) was added to a final 
concentration of 25 μM to nocodazole-synchronized MCF-7 or Hela cells at the time of release from 
nocodazole. Cells were fixed and stained according to the above protocol after 70 min. 
4.8. Flow Cytometry 
MCF-7 cells were plated and transfected according to above siRNA protocol and grown in 60 mm 
plates for 48 h after transfection. Cells were trypsinized briefly with 0.25% Trypsin-EDTA 
(Invitrogen), pelleted by centrifugation at 200 g for 5 min, resuspended in PBS, fixed by the gradual 
addition of 100% ethanol while vortexing, incubated on ice for 15 min, centrifuged at 453 g for 5 min, 
and resuspended in staining solution (0.05 mg/mL propidium iodide, 0.1 mg/mL RNaseA, 0.05% 
Triton X-100 in PBS). Stained cells were mixed twice with a 26 gauge needle and syringe and passed 
through a 40 μm filter. Analysis was performed on a Beckman-Coulter FC 500 series flow cytometer. 
Triplicate samples were analyzed and the experiment was repeated twice. 
4.9. Statistical Analysis 
A two-tailed, paired t-test was used to compare experiments performed in parallel. All experiments 
data are representative of at least three independent experiments. For analysis of chromosome 
segregation defects a minimum of 100 cells were analyzed per experiment. A p-value of <0.05 was 
considered statistically significant.  
5. Conclusions 
These studies are the first to implicate p190B RhoGAP as a regulator of mitosis. Future studies  
will be required to evaluate the contribution of p190B’s mitotic functions to normal and neoplastic 
development in vivo. 
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